Meet NalaGenetics! This healthtech startup uses genetic testing solutions to help patients get better outcomes. They just raised a $12.6M Series A to take this even further.

• Their solutions help prevent disease and provide patients with personalized and more effective prescriptions.
• They have over 40 hospital and clinic partners and are active in Singapore and Indonesia.

No bad stuff. Genetic testing also helps us avoid potentially fatal prescriptions and be aware of risks, like potential disease recurrence or permanent side effects. (Yikes!)

• This is through testing genes' reactions to certain drugs and food.

Who cashed in? Intudo Ventures and Vulcan Capital co-led the round. The Agency for Science, Technology and Research (ASTAR), Dexa International and Diagnos Laboratories also joined in.

👨🏻‍🔬 How it works

There's a lot of science and technical jargon to this, but in a nutshell, they do:

Genetic testing. Cheaper and more convenient genetic tests.

Analytics. Data-backed recommendations and prescriptions for patients and doctors.

End-to-end services. Their Clinical Decision Support software helps clinics and hospitals test, analyze, report and integrate genetic information into healthcare systems.

🏥 Coming to a hospital near you

They're developing new modules for other diseases such as cancer, cardiometabolic diseases (like diabetes) and neurodegenerative conditions (like Alzheimer's).

• They're also looking to expand to new countries like Malaysia.